Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Wichita Bio is an innovative medical technology company specializing in the development of nanofiber-based biomaterials for bone regeneration and orthopedic repair. The company's core technology utilizes advanced nanotechnology to create synthetic bone graft substitutes that closely mimic the natural human bone environment, promoting faster and more effective healing. These biomimetic scaffolds are designed for use in a variety of clinical applications, including spinal fusion, dental reconstruction, and the treatment of complex bone fractures. By offering a high-performance alternative to autografts and allografts, Wichita Bio aims to improve surgical outcomes and reduce patient recovery times. The company is a spin-off from Wichita State University and continues to leverage academic research to drive its product pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Wichita Bio.